Clinicopathological significance of  CHFR  promoter methylation in gastric cancer: a meta-analysis

Yong Ding; Hai-Feng Lian; Yaowu Du

doi:10.18632/oncotarget.23394

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Clinicopathological significance of CHFR promoter methylation in gastric cancer: a meta-analysis

Yong Ding, Hai-Feng Lian and Yaowu Du _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:10083-10090. https://doi.org/10.18632/oncotarget.23394

Metrics: PDF 1865 views | HTML 2636 views | ?

Abstract

Yong Ding1, Hai-Feng Lian2 and Yaowu Du3

1School of Basic Medical Science, Henan University, Kaifeng, 475004, China

2Department of Gastroenterology, Affiliated Hospital of Binzhou Medical College, Binzhou, 256600, China

3Laboratory for Nanomedicine, School of Basic Medical Science, Henan University, Kaifeng, 475004, China

Correspondence to:

Yaowu Du, email: [email protected]

Keywords: CHFR; methylation; gastric cancer; biomarker; drug target

Received: August 21, 2017 Accepted: November 16, 2017 Published: December 16, 2017

ABSTRACT

The mitotic checkpoint gene (CHFR) (Checkpoint with Forkhead-associated and Ring finger domains is a G2 phase/mitosis checkpoint and tumor-suppressor gene. Recent studies have reported the relationship of CHFR promoter methylation with clinicopathological significance of gastric cancer. However, the results remain unclear due to small size of sample. We pooled 15 studies including 827 gastric cancer patients and conducted a meta-analysis to investigate the clinicopathological significance of CHFR promoter methylation in gastric cancer. Our data revealed that the frequency of CHFR promoter methylation was higher in gastric cancer than in normal gastric tissue, Odd Ratio (OR) was 10.12 with 95% CI 5.17–19.79, p < 0.00001. Additionally, the rate of CHFR promoter methylation was significantly increased in high grade of gastric cancer compared to low grade, OR was 1.64 with 95% CI 1.00–2.68, p = 0.05. CHFR methylation was significantly associated with the positive lymph node metastasis, OR was 1.56 with 95% CI 1.05–2.32, p = 0.03. We concluded that CHFR could serve as a biomarker for diagnosis of gastric cancer, and a drug target for development of gene therapy in gastric cancer. CHFR promoter methylation is associated with tumor poor differentiation and lymph node metastasis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23394

Publication Alerts

Meta-Analysis:

Clinicopathological significance of CHFR promoter methylation in gastric cancer: a meta-analysis

Abstract